Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2004 3
2005 1
2006 3
2007 3
2008 2
2009 3
2010 1
2011 2
2012 7
2013 3
2014 7
2015 9
2016 3
2017 7
2018 4
2019 4
2020 7
2021 6
2022 5
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
Gene replacement therapy for Lafora disease in the Epm2a -/- mouse model.
Zafra-Puerta L, Burgos DF, Iglesias-Cabeza N, González-Fernández J, Sánchez-Martín G, Sánchez MP, Serratosa JM. Zafra-Puerta L, et al. Among authors: serratosa jm. bioRxiv [Preprint]. 2023 Dec 14:2023.12.14.571636. doi: 10.1101/2023.12.14.571636. bioRxiv. 2023. PMID: 38168354 Free PMC article. Preprint.
Antiepileptogenesis after stroke-trials and tribulations: Methodological challenges and recruitment results of a Phase II study with eslicarbazepine acetate.
Koepp MJ, Trinka E, Mah YH, Bentes C, Knake S, Gigli GL, Serratosa JM, Zelano J, Magalhães LM, Pereira A, Moreira J, Soares-da-Silva P. Koepp MJ, et al. Among authors: serratosa jm. Epilepsia Open. 2023 Sep;8(3):1190-1201. doi: 10.1002/epi4.12735. Epub 2023 Jun 12. Epilepsia Open. 2023. PMID: 36944588 Free PMC article. Clinical Trial.
Number needed to treat and associated cost analysis of cenobamate versus third-generation anti-seizure medications for the treatment of focal-onset seizures in patients with drug-resistant epilepsy in Spain.
Villanueva V, Serratosa JM, Toledo M, Ángel Calleja M, Navarro A, Sabaniego J, Pérez-Domper P, Álvarez-Barón E, Subías S, Gil A. Villanueva V, et al. Among authors: serratosa jm. Epilepsy Behav. 2023 Feb;139:109054. doi: 10.1016/j.yebeh.2022.109054. Epub 2023 Jan 3. Epilepsy Behav. 2023. PMID: 36603345 Free article.
Early Treatment with Metformin Improves Neurological Outcomes in Lafora Disease.
Burgos DF, Machío-Castello M, Iglesias-Cabeza N, Giráldez BG, González-Fernández J, Sánchez-Martín G, Sánchez MP, Serratosa JM. Burgos DF, et al. Among authors: serratosa jm. Neurotherapeutics. 2023 Jan;20(1):230-244. doi: 10.1007/s13311-022-01304-w. Epub 2022 Oct 27. Neurotherapeutics. 2023. PMID: 36303102 Free PMC article.
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain.
Ángel Calleja M, Navarro A, Serratosa JM, Toledo M, Villanueva V, Subías Labazuy S, Gil A. Ángel Calleja M, et al. Expert Rev Pharmacoecon Outcomes Res. 2022 Oct;22(7):1127-1136. doi: 10.1080/14737167.2022.2107507. Epub 2022 Aug 3. Expert Rev Pharmacoecon Outcomes Res. 2022. PMID: 35904256 Free article.
Onset of efficacy and adverse events during Cenobamate titration period.
Steinhoff BJ, Ben-Menachem E, Brandt C, García Morales I, Rosenfeld WE, Santamarina E, Serratosa JM. Steinhoff BJ, et al. Among authors: serratosa jm. Acta Neurol Scand. 2022 Sep;146(3):265-275. doi: 10.1111/ane.13659. Epub 2022 Jun 16. Acta Neurol Scand. 2022. PMID: 35711112 Free PMC article. Clinical Trial.
85 results